A single subtype of heterotrimeric G protein-coupled receptor controls both nitric oxide (NO) (sensitive to L-arginine analogues) and endothelium-derived hyperpolarizing factor (EDHF) (sensitive to high-external K ϩ and apamine) production by the vascular endothelium leading to dilation. We hypothesized that ␣and ␤␥-subunits of the G protein serve as distinct intermediates to produce NO and EDHF. In pressurized resistance arteries, selective pinocytotic endothelial incorporation of specific antibodies (Abs) directed against ␣ q/11 -subunits abolished acetylcholine (Ach)-mediated dilation but failed to influence oxymetazoline (Oxy, ␣ 2 -adrenergic receptor agonist)-induced dilation. In contrast, ␣ i1-2 -subunit Abs prevented Oxy-but not Ach-induced dilation. Thus, as expected, endothelial muscarinic and ␣ 2 -adrenoceptors couple to G q protein and G i proteins, respectively. ␤-subunit Abs reduced both Ach-and Oxy-induced dilation. The ␤-subunit Abs abolished the nitro-L-arginine (L-NNA)-sensitive component but did not impair the high-external K ϩ -sensitive component of the dilation induced by Ach and Oxy. Thus, G protein ␤-subunits primarily accounted for NO production. Neutralization of Hsp90 and inhibition of the phospholipase C by U73122 (1 mol/L) or intracellular Ca 2ϩ buffering with BAPTA-AM (10 mol/L) sharply reduced NO-dependent but not K ϩ -sensitive dilation. In conclusion, mobilization of the G protein ␤-subunit is pivotal to NO-dependent dilation triggered through muscarinic and ␣ 2 -adrenergic receptors. In contrast, receptor-operated EDHF-dependent dilation was insensitive to ␤-subunit Abs. Although not directly activating the NO pathway, ␣-subunit activation is an absolute prerequisite for receptor-operated endothelium-dependent dilation of resistance arteries. (Circ Res. 2001;89:716-722.) 
S ignaling via the large family of G protein-coupled receptors (GPCRs) leads to a variety of cellular responses, ranging from regulation of intracellular level of AMPc to stimulation of gene transcription. 1 G proteins are made of 3 subunits, ␣, ␤, and ␥. Overexpression of different subtypes of receptors and classes of G protein has been the preferred experimental strategy to assess receptor-to-G protein coupling. 2, 3 Although G protein ␣-subunits have been initially considered as the major determinant of intracellular pathway activation, it is now clear that activation of ␤␥-subunits triggers specific intracellular responses. 4 For instance, G␤␥subunits have been shown to increase the activity of adenylate cyclase, 5, 6 MAP kinases, 7 phospholipase C, 8 and phospholipase A 2 . 9 This implies that G protein subunits serve as pivotal determinants of downstream intracellular events.
Most of the attention has been directed at linking receptor activation to specific subtypes of ␣-subunits of the G protein as ␣ i , ␣ s , and ␣ q . 10 -17 For example, using neutralizing antibodies (Abs) for specific subtypes of ␣-subunits, Liao and Homcy 10 demonstrated that ␣ 2 -adrenergic receptors (␣ 2 -ARs) coupled to G i2 -subunits in cultured endothelial cells. Further-more, it was shown that angiotensin II-stimulated phospholipase D activity was reduced by G␤-subunit Abs in cultured smooth muscle cells and that the ␤␥-subunit complex thus activated this enzyme. 18 The differential production of endothelium-derived relaxing factors with respect to G protein coupling has not been considered earlier.
In this connection, it is now recognized that in vascular endothelial cells, a single subtype of receptor can lead to the production of both nitric oxide (NO) (sensitive to L-arginine analogues) and endothelium-derived hyperpolarizing factor (EDHF) (sensitive to high-external K ϩ and apamine). This induces endothelium-dependent dilation. 19 -23 This led us to hypothesize that the receptor-operated release of endothelium-derived relaxing factor reflects the specific coupling of G␣-or G␤␥-subunits to either NO or EDHF production. To address this issue, we have developed a unique model allowing selective endothelial incorporation of neutralizing Abs in pressurized resistance arteries and measurements of vascular diameter. Therefore, the specific objectives of the present study are (1) to investigate the differential contribution of G protein ␣and ␤-subunits to NO-and EDHF-dependent dilation and (2) to elucidate the distinct intracellular effectors involved in these processes.
Material and Methods

Vascular Preparation
Experiments were conducted, as previously described, 24 on isolated resistance arteries (Ϸ200 m) of the mesenteric bed of male New Zealand White rabbits (weight range: 2.5 to 3.5 kg; Charles River Laboratories, St Constant, Quebec, Canada). The procedures and protocols were in accordance with our institution guidelines and the Guide for the Care and the Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23). Rabbits were anesthetized with an intravenous injection of sodium pentobarbitol (65 mg · kg Ϫ1 ) and exsanguinated. The mesenteric bed was harvested and a fifth branch of the mesenteric artery was dissected out and placed in ice-cold physiological salt solution (PSS) containing indomethacin (10 mol/L). A 2-to 3-mm length arterial segment was isolated and pressurized at 60 mm Hg. 24
Incorporation of Antibodies Inside Endothelial Cells
This method is based on osmotic lysis of pinocytic vesicules, previously described by Okada and Rechsteiner. 25 We used the Influx pinocytic cell-loading reagent kit (Molecular Probes). Pressurized vessels were first intraluminally perfused (2 L · min Ϫ1 ) with a hyperosmotic solution containing the Abs for 60 minutes. Abs were used at a dilution ranging from 1:1000 to 1:100. Arteries were then perfused with the hypo-osmotic solution for 10 minutes. Finally, vessels were perfused with normal PSS followed by a 30-minute equilibration period. Experiments performed without Abs in the hyperosmotic solution are identified as vehicle experiments. In control experiments, vessels were not subjected to the internalization protocol. Internalization of FITC-labeled IgG was restricted to the endothelium, as revealed by confocal microscopy imaging ( Figure  1 ). Furthermore, none of the Abs used in this study altered smooth muscle reactivity to phenylephrine (PE), confirming the selective incorporation of the Abs in the endothelium (Table) .
Experimental Protocols
The relative contribution of NO and EDHF to agonist-mediated dilation in no-flow conditions was determined after exposure to N -nitro-Larginine (L-NNA) (10 mol/L) or KCl-PSS (25 mmol/L). In vehicle conditions, the dilation induced by acetylcholine (Ach) in the presence of L-NNA was blocked by further addition of 25 mmol/L KCl-PSS. On the other hand, the dilation induced by Ach in the presence of 25 mmol/L KCl-PSS was blocked by further addition of L-NNA (data not shown). To determine the G protein subtype coupled to muscarinic and ␣ 2 -ARs, cumulative concentration-response curves were constructed with Ach (0.1 nmol/L to 30 mol/L) or oxymetazoline (Oxy) (0.1 nmol/L to 30 mol/L) on preconstricted vessels (PE, 10 mol/L). These experiments were repeated after incorporation of the anti-␣subunit Ab. Similarly, the effect of the anti-␣-subunit Ab on substance P-induced dilation was investigated.
To determine the involvement of G protein ␤-subunit in NO-or EDHF-mediated dilation to the agonists, experiments were repeated after endothelial incorporation of anti-G␤-subunit Abs in the absence or presence of L-NNA (10 mol/L) or KCl-PSS (25 mmol/L).
We then investigated the contribution of Hsp90, phospholipase C (PLC), and intracellular free Ca 2ϩ in NO-and EDHF-mediated dilation. Selective endothelial inhibition of the PLC was achieved by intraluminal perfusion with U73122 (1 mol/L during 30 minutes) or 
Percent Reduction in Internal Diameter in the Various Experimental Conditions
Myogenic Tone
Abs were used at a dilution of 1:100; L-NNA: 10 mol/L; K ϩ : 25 mmol/L KCl-PSS; U73122: 1 mol/L; and U73343: 1 mol/L. All physiological solutions contained indomethacin (10 mol/L).
*PϽ0.05 vs vehicle (ANOVA, Scheffé 's F test).
its inactive analogue, U73343. On the other hand, buffering of endothelial cell intracellular Ca 2ϩ was achieved by intraluminal perfusion of BAPTA-AM (10 mol/L) during 25 minutes followed by a 30-minute washout period. The term "EDHF" used in this study refers to the KCl-and apamine-sensitive, L-NNA-and indomethacin-resistant component of endothelium-dependent vasodilation. 20,26 -29 
Statistical Analysis
Only two vessels were used from each rabbit. Only one protocol was performed per vessel. n refers to the number of rabbits used in each protocol. Half-maximum effective concentrations (EC 50 ) of Ach and Oxy were measured from each individual dose-response curve using a logistic curve-fitting program (Allfit, Dr Deléan, University of Montréal). The pD 2 value is the negative log of the EC 50 . Results were expressed as meanϮSE. At the end of the protocol, the maximal diameter (D max ) was determined by changing the PSS to a Ca 2ϩ -free PSS containing sodium nitroprusside (10 mol/L) and EGTA (1 mmol/L).
For each protocol, basal diameter in no-flow condition was determined at the end of the 30-minute equilibration period. Myogenic tone (at 60 mm Hg) represents the difference between the D max and the basal diameter, and is expressed as a percentage of the D max . PE-induced constriction is expressed as a percentage of the D max . Agonistinduced dilation is expressed as a percentage of the initial PEinduced constriction.
Statistical differences between two groups of data were determined using an unpaired Student's t test. For multiple comparisons, an ANOVA was used followed by a Scheffé's F test. A P value Ͻ0.05 was considered significant.
Drugs
Ach, apamine, indomethacin, L-NNA, Oxy, phenylephrine (PE), substance P, and sodium nitroprusside (SNP) were purchased from Sigma. BAPTA-AM, U73122, and U73343 were purchased from Calbiochem. All drugs were added directly to the vessel chamber and final concentration is given. They were prepared daily in distilled water except for indomethacin and the U compounds, which were prepared in ethanol (final dilution of ethanol was 0.1%). BAPTA-AM was prepared according to a method developed by Yashiro and Duling 30 and used at 10 mol/L; 5 mg BAPTA was dissolved in 1 mL of hygroscopic DMSO (stable under argon) and vortex. From this solution, 6.1 L was added to 4 mL of Ca 2ϩ PSS containing 1% (vol/vol) albumin. Equimolar amounts of NaCl were replaced with KCl to prepare K ϩ -rich solution (KCl-PSS). Antibodies were purchased from Calbiochem and Transduction Laboratories (Hsp90). Their characteristics were as follows: G␣ q/11 -subunit Abs (Internal, 283-300); G␣ i1 -and G␣ i2 -subunit Abs (C-terminal, 345-354 and 346-355); G␤ common -subunit Abs (Internal, 127-139); and Hsp90 (clone 68, C-terminal, 586-732).
Results
Characterization of Ach-and Oxy-Induced Endothelium-Dependent Dilation
The relative contribution of NO and EDHF to agonistmediated dilation was determined after exposure to L-NNA (10 mol/L) or KCl-PSS (25 mmol/L). The residual dilation to Ach or Oxy after L-NNA was blocked by 25 mmol/L KCl-PSS. Apamine (0.1 mol/L) alone also prevented L-NNA-resistant dilation (Ϫ0.4Ϯ2.6% dilation, nϭ6, PϽ0.05) as compared with 93Ϯ1% dilation in the absence of apamine (nϭ6 per group). In separate experiments, the residual dilation to Ach or Oxy in the presence of 25 mmol/L KCl-PSS was abolished by L-NNA, consistent with the involvement of NO. Thus, in isolated pressurized resistance arteries, receptor-operated dilation involves both NO-dependent mechanism and a KCl-and apamine-sensitive process resembling the effects of EDHF.
Incorporation Protocol (Vehicle)
In control conditions, Ach (0.1 nmol/L to 30 mol/L, nϭ6) induced a concentration-dependent dilation with a pD 2 value of 6.2Ϯ0.3 and a maximal dilation (E max ) of 72Ϯ11%. This dilatory response was not altered by the incorporation protocol (vehicle, nϭ5; pD 2 ϭ6.6Ϯ0.1, E max ϭ69Ϯ13%). Similarly, Oxy-induced dilation (0.1 nmol/L to 30 mol/L, nϭ6) was not affected by the incorporation protocol (control: pD 2 ϭ5.9Ϯ0.2, E max ϭ44Ϯ8%, nϭ7; vehicle: pD 2 ϭ5.8Ϯ0.2, E max ϭ47Ϯ2%, nϭ6). Neither myogenic tone nor PE-induced contractions were altered by vehicle (Table) .
Endothelial Incorporation of G Protein ␣-Subunit Antibodies
Incorporation of anti-G␣ q/11 Abs at a dilution of 1/100 substantially reduced Ach-induced dilation without affecting Oxy-induced dilation (Figure 2) . At lower dilutions, the Ab dose dependently reduced (PϽ0.05) Ach-induced dilation. A 1/100 dilution of Abs was used in all subsequent experiments. Incorporation of anti-G␣ i1-2 Abs had no effect on Achinduced dilation (Figure 3 ). As for Ach, the anti-G␣ q/11 Ab prevented substance P-induced dilation, whereas the anti-G␣ i1-2 Ab had no effect (online Figure 1 , available in the data supplement at http://www.circresaha.org). In contrast, Oxyinduced dilation was reversed to a contraction (PϽ0.05) by anti-G␣ i1-2 Abs but was not significantly affected by anti-G␣ q/11 Abs (Figure 4 ). None of the Abs altered myogenic tone or PE-induced contraction (Table) .
Endothelial Incorporation of G Protein ␤-Subunit Antibodies
Incorporation of anti-G␤ common -subunit Abs reduced both Achand Oxy-induced dilation (Figures 5 and 7) . Maximal dilation to Ach and Oxy was reduced (PϽ0.05) from 69Ϯ13% and 47Ϯ2% to 44Ϯ7% and 28Ϯ3%, respectively. The residual dilation to Ach and Oxy persisting after the incorporation of G␤-subunit Abs was prevented (PϽ0.05) by 25 mmol/L KCl-PSS ( Figure 5 and online Figure 2 ). Conversely, the residual dilation to Ach and Oxy persisting after the incorporation of G␤-subunit Abs was not altered by L-NNA ( Figure 6 and online Figure 3 ). Thus, G␤-subunit Abs selectively prevented Ach-and Oxy-induced NO-dependent dilation. Incorporation of G␤-subunit Abs increased myogenic tone but failed to influence PE-induced contractions (Table) . G␤-subunit Abs did not influence L-NNA-and high-external K ϩ -induced contraction.
Involvement of PLC in NO-Mediated Dilation
Pressurized arteries were treated intraluminally with the PLC inhibitor U73122 (1 mol/L, 30 minutes). U73122 prevented (PϽ0.05) Ach-induced NO-dependent dilation (in the presence of 25 mmol/L KCl-PSS). In contrast, U73122 failed to alter L-NNA-resistant dilation (Figure 7) . Because PEinduced contraction was not altered after U73122 (Table) , blockade of the PLC was most likely limited to the endothelial cells. Furthermore, external application of U73122 (1 mol/L, 30 minutes) limited the peak PE contraction to 40% of its normal amplitude, and the contraction was no longer sustained (data not shown). The inactive form of the PLC inhibitor U73343 had no influence on Ach (10 mol/L)induced NO-dependent dilation (45Ϯ3% compared with 52Ϯ5% in absence of U73343; nϭ6).
Involvement of Intracellular Ca 2؉ in NO-Mediated Dilation
Pressurized arteries were treated intraluminally with the Ca 2ϩ chelator BAPTA-AM (10 mol/L). Ach-induced dilation was maintained in the presence of BAPTA-AM (87Ϯ5% versus control, 72Ϯ11%; nϭ5 per group). The NO-dependent component of Ach-induced dilation (in the presence of 25 mmol/L KCl-PSS) was reduced (PϽ0.05) by BAPTA-AM (23Ϯ10% versus 55Ϯ7% in the absence of BAPTA-AM; nϭ6 per group). In contrast, endothelial incorporation of BAPTA-AM did not reduce Ach-induced KCl-sensitive dilation (after NO synthase blockade) but in fact caused a significant (PϽ0.05) increase from 59Ϯ5% in control to 86Ϯ8% after BAPTA-AM (nϭ5 per group). PE-induced contraction was not affected by BAPTA-AM in the presence of L-NNA and 25 mmol/L KCl-PSS (63Ϯ10% and 59Ϯ6%, respectively) when compared with control responses (Table) . SNP (1 mol/L)-induced maximal dilation was not altered by BAPTA-AM (data not shown).
Involvement of Hsp90 in NO-Mediated Dilation
Incorporation of anti-Hsp90 Abs reduced NO-mediated dilation (22Ϯ5%, PϽ0.05, nϭ7) induced by Ach (10 mol/L), as compared with vehicle in the presence of 25 mmol/L KCl-PSS. EDHF-mediated dilation was not altered (92Ϯ2%, nϭ7). The preconstriction induced by PE was not altered by Hsp90 Abs in the presence of L-NNA (70Ϯ4%) and 25 mmol/L KCl (72Ϯ5%), as compared with vehicle (Table) .
Discussion
In the present study, we have demonstrated that receptoroperated NO-dependent and NO-independent dilation of pressurized resistance arteries involved distinct pathways. NO-dependent dilation was prevented by selectively targeting the G protein ␤-subunit with neutralizing Abs. Our data further demonstrate that PLC activation accounts for Ca 2ϩdependent NO production. In contrast, NO-independent but KCl-and apamine-sensitive (presumably EDHF) dilation 20,26 -29 was resistant to blockade of G protein ␤-subunits, independent of PLC activity and a change in intracellular Ca 2ϩ levels. Presumably, G protein ␣-subunits accounted for NO-independent dilation.
Both NO and EDHF are involved in the endotheliumdependent dilator responses to ␣ 2 -AR and muscarinic receptor agonists. 31, 32 Conceivably, the differential production of NO and EDHF could reflect selective activation of ␣and ␤␥-subunits of the G protein. To address that issue, we used neutralizing antibodies selectively internalized into the endothelium of pressurized vessels. Our data indicate that this approach can adequately target endothelial cells (Figure 1 ) and avoid the confounding effect of smooth muscle cell Ab internalization as demonstrated by the stability of the con-traction induced by PE (Table) . Although this approach has been successfully used by others to target G protein subunits in cultured endothelial and smooth muscle cells, 10, 18 to our best knowledge this study is the first to use G protein subunit Abs to specifically target endothelial cells in pressurized vessels. This allowed us to link the effect of endothelial G protein subunit inhibition to overall vascular responses. As a consequence, neutralization of the endothelial ␣ 2 -AR pathway partly revealed the smooth muscle contractile response to Oxy (Figure 4 ), 24 which represents another demonstration of the selective endothelial incorporation of the antibodies. Ach, on the other hand, has no effect in denuded mesenteric vessels (data not shown), which render the endothelium the unique functional target of the muscarinic agonist.
Consistent with earlier studies, our data demonstrate the specificity of the coupling of ␣ 2 -ARs to G i proteins 32, 33 and substance P 32 and muscarinic receptors to G q proteins. 34, 35 As expected, anti-G␣ q -subunit Abs selectively abolished substance P-and Ach-induced endothelium-dependent dilation, whereas anti-G␣ i -subunit Abs selectively abolished ␣ 2 -ARmediated endothelium-dependent dilation. Thus, ␣-subunit activation is an absolute prerequisite for receptor-operated endothelium-dependent dilation of resistance arteries. Apparently, ␣-subunit activation by receptor stimulation is an essential initial step in NO and EDHF production.
Biochemical studies have demonstrated that ␣and ␤␥subunits from a single G protein subtype could influence distinct intracellular processes, 3, 4 such as NO and EDHF production. To directly address that issue, we have created experimental conditions to separate NO-mediated (in the presence of indomethacin and high-external K ϩ ) and EDHFmediated (in the presence of indomethacin and L-NNA) agonist-induced dilations as described by others. 26 -29 Neutralization of G protein ␤-subunits prevented NO-dependent dilation induced by Ach and Oxy ( Figure 5 and online Figure  2 ). The process subtending EDHF-dependent dilation clearly differs from that of NO-dependent dilation and was independent of G␤-subunit activation ( Figure 5 and online Figure 2 ). Conceivably, in addition to being the initial step in receptormediated G protein activation, ␣-subunit activation may then selectively trigger EDHF production.
It has been shown that on G protein activation, ␤␥-subunits activate PLC and increase intracellular free Ca 2ϩ . 8 To ensure that our experimental approach did not disrupt the pathway considered to normally account for NO production, 30,36 -38 we have examined the effects of PLC inhibition, Ca 2ϩ buffering, and neutralization of Hsp90 on NO-dependent dilation. Inhibition of PLC (Figure 7) prevented NO-but not EDHFdependent Ach-mediated dilation. Consistent with this finding, BAPTA-AM reduced NO-dependent dilation but failed to alter EDHF-dependent dilation. This partial inhibition of NO-mediated dilation with BAPTA-AM is consistent with data obtained in similar experimental conditions 30 and may be owing to the lack of total Ca 2ϩ clamp, despite the sharp reduction in intracellular Ca 2ϩ previously reported. 30 Alternatively, this may reflect the Ca 2ϩ -independent, Hsp90mediated sustained activation of NO synthase. 39 Reduction in NO-but not EDHF-dependent dilation by endothelial incorporation of Hsp90 Abs further confirms the specificity and the high degree of compartmentalization of the NO pathway. Thus, Ca 2ϩ -dependent NO production most likely involved G␤␥-subunit-dependent PLC activation. 18, 40 EDHF production clearly differed from NO production, as it was insensitive to Hsp90 neutralization and PLC blockade and was Ca 2ϩ -independent.
In contrast to earlier studies performed in conductance arteries, 23, 41, 42 the present data indicate that the NOindependent dilation of resistance vessels was insensitive to Ca 2ϩ buffering with BAPTA-AM. One mechanism by which activation of muscarinic receptors can lead to NO-and Ca 2ϩ -independent dilation is through an increase K ϩ efflux from endothelial cells, 43 which can induce hyperpolarization. 44 Because of the direct contact between endothelial and smooth muscle cells in resistance arteries, hyperpolarization could be transmitted from endothelial to smooth muscle cells by myoendothelial gap junctions. 30, 45, 46 In that eventuality, the endothelium-dependent hyperpolarization would not require the Ca 2ϩ -dependent synthesis of an EDHF. 45 In support of this hypothesis, agonist-induced endothelium-dependent vasodilation of resistance arteries in endothelial NO synthase knockout mice is mediated by an EDHF-like principle that requires functional gap junctions but not NO, prostacyclin, or a cytochrome P450 metabolite production. 29, 45 In conductance arteries, myoendothelial junctions are lacking. This may explain why the production of an EDHF by the endothelium is required for endothelium-dependent hyperpolarization of smooth muscle cells. 47 The responses observed after G protein ␣-subunit Ab internalization should be interpreted with caution because neutralization of endothelial G protein ␣-subunits prevented receptor/G protein coupling. This is an inherent problem of targeting G protein ␣-subunits. What our data convincingly show is the close association between NO-dependent responses and G protein ␤-subunit activation. Consequently, the residual dilatory response resistant to ␤-subunit blockade most likely reflected ␣-subunit activation. Such a model has been previously described with neutralizing Abs in patchclamp studies using the inside-out configuration. 17 These authors demonstrated that 11,12-epoxyeicosatrienoic acidinduced Ca 2ϩ -sensitive K ϩ channel activation was mediated by G␣ s -subunits but not ␤␥-subunits in isolated smooth muscle cells. Thus, it is conceivable that in endothelial cells of pressurized resistance arteries a direct coupling between muscarinic receptors, G␣ q -subunits, and K ϩ channels may be involved and lead to NO-independent dilation.
In conclusion, mobilization of the G protein ␤-subunit is pivotal to NO-dependent dilation triggered through endothelial muscarinic and ␣ 2 -adrenergic receptors. In contrast, receptor-operated EDHF-dependent dilation was insensitive to ␤-subunit Abs. Although not directly activating the NO pathway, ␣-subunit activation is an absolute prerequisite for receptor-operated endothelium-dependent dilation of resistance arteries.
